Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human OX40 / TNFRSF4 / CD134 Protein, His-Tag, 100µg  

Recombinant Human OX40 / TNFRSF4 / CD134 Protein, His-Tag, 100µg

Recombinant Human OX40 / TNFRSF4 / CD134 Protein, His Tag (MALS verified) (rh TNFRSF4 / OX40 / CD134) Leu 29 - Ala 216 was produced in human 293 cells (HEK293) with a polyhistidine tag.

Synonym: recombinant, human, protein, TNFRSF4, OX40, CD134, OX40L receptor, ACT35, TXGP1L

More details

OX0-H5224-100

Availability: within 7 days

336,00 €

Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Source
Recombinant Human OX40 Protein, His Tag (MALS verified) (OX0-H5224) is expressed from human 293 cells (HEK293). It contains AA Leu 29 - Ala 216 (Accession # P43489-1).
Predicted N-terminus: Leu 29

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.0 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rh TNFRSF4 / OX40 / CD134 by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "The Anti-Inflammatory and Anti-Pruritus Mechanisms of Huanglian Jiedu Decoction in the Treatment of Atopic Dermatitis"
Xu, Chen, Zhang et al
Front Pharmacol (2021) 12, 735295
(2) "March1-overexpressed dendritic cells downregulate Th1/Th2 ratio in asthma through promoting OX40L"
Gu, Guo, Zhang et al
Int Immunopharmacol (2021) 103, 108444
(3) "DNA Methylation and mRNA Expression of OX40 (TNFRSF4) and GITR (TNFRSF18, AITR) in Head and Neck Squamous Cell Carcinoma Correlates with HPV Status, Mutational Load, an Interferon-γ Signature, Signatures of Immune Infiltrates, and Survival"
Loick, Fröhlich, Gabrielpillai et al
J Immunother (2021)
Showing 1-3 of 1761 papers.

Citations

(1) "Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist"
Authors: Upadhyaya P, Lahdenranta J, Hurov K, et al.
Journal: Journal for immunotherapy of cancer 2021
Application: SPR
(2) "Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR"
Authors: Simons JF, Lim YW, Carter KP, et al
Journal: Mabs 2020
Application: Flow cytometry
(3) "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy"
Authors: Fromm G, et al
Journal: J ImmunoTher Cancer 2018
Application: SPR

The following products could also be interesting for you: